Abstract

Research Article

Explicating the presentations of Acanthamoeba keratitis with special concern in the COVID-19 pandemic ambient

Chrysanthus Chukwuma Sr*

Published: 18 March, 2021 | Volume 4 - Issue 1 | Pages: 010-015

This article presents an overview of information regarding Acanthamoeba keratitis per epidemiology, host-pathogen interactions, clinical manifestations, risk factors, environmental implications, diagnosis, treatment and management as well as COVID-19 characteristics which may be taken into cognizance for suspected infected patients, researchers and ophthalmologic practitioners. Acanthamoeba spp. is pathogenetically ubiquitous in nature. Acanthamoeba keratitis is considerably an ocular-threatening and debilitating keratitis that exhibits contumacious characteristics which hinder or impede treatment or management. At inception, Acanthamoeba generally depicts atypical clinical features which are frequently misdiagnosed as other microbial keratitis. Fundamentally, it constitutes a rare corneal infection of which the aetiologic agent is the protozoon Acanthamoeba spp. in contact lens wearers, presenting features of severe ophthalmic distress, blurred vision, blepharospasm, ocular excoriation, extraneous entity sensation and photophobia culminating in aberrant visual functionality. These are perspicuously due to retarded prompt and adequate treatment and management. Personal and environmental hygiene, especially on the hands, face and ocular areas as advised for the COVID-19 protocol could prevent contamination and dissemination of Acanthamoeba keratitis infection. The differentiating relatedness of Acanthamoeba keratitis, COVID-19 ophthalmologic infections and other ocular problems may not have been clearly elucidated.

Read Full Article HTML DOI: 10.29328/journal.ijcmbt.1001020 Cite this Article Read Full Article PDF

Keywords:

Emerging and reemerging infectious disease; Prevention; Hygiene; Diagnosis; Evaluation; Microbial keratitis; COVID-19

References

  1. Merritt J, Hogan RN. Bilateral Acanthamoeba panophthalmitis: A rare and unique case. Am J Ophthalmol Case Rep. 2020.
  2. Chukwuma Sr C. Comments on the environmental health implications of Acanthamoeba. Int J Env Hlth Res. 1996; 6: 49-54.
  3. Chukwuma Sr C. Information and communication needs in the administration of ibuprofen of symptoms in COVID-19 patients. J Med Res. 2020; 6: 128-130.
  4. Chukwuma Sr C. Ecological analysis of the COVID-19 pandemic for restoration and sustainability. Res Adv Pharm Life Sci. 2021; 3: 8-12.
  5. Maycock NJ, Jayaswal R. Update on Acanthamoeba keratitis: Diagnosis, treatment and outcomes. Cornea. 2016; 35: 713-720. PubMed: https://pubmed.ncbi.nlm.nih.gov/26989955/
  6. Somani S, Ranquillo Y (Moshirfar M ed.). Acanthamoeba Keratitis Article. 2021. PubMed: https://www.statpearls.com/ArticleLibrary/viewarticle/81120
  7. Kim JH, Matin A, Shin HJ, Park H, Yoo KT, et al. Functional roles of mannose-binding protein in the adhesion, cytotoxicity and phagocytosis of Acanthamoeba castenani. Exp Parasitol. 2012; 32: 287-292. PubMed: https://pubmed.ncbi.nlm.nih.gov/22940016/
  8. Szentmary N, Daas L, Shi L, Laurik KC, Lepper S, et al. Acanthamoeba keratitis - Clinical signs, differential diagnosis and treatment. J Curr Ophthalmol. 2019; 31: 16–23. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407156/
  9. Garg P, Kalra P, Joseph J. Non-contact lens related Acanthamoeba keratitis. Int J Ophthalmol. 2017; 65: 1079–1086. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700572/
  10. Chukwuma, Sr, C. Microsporidium in AIDS and HIV-infected patients: A perspective. East Afri Med J. 1996; 73: 72-75.
  11. Khurana S, Sharma M. Parasitic keratitis - An under-reported entity. Trop Parasitol. 2020; 10: 12-17. PubMed: https://pubmed.ncbi.nlm.nih.gov/32775286/
  12. de Lacerda AG, Lira M. Acanthamoeba keratitis: a review of biology,pathophysiology and epidemiology. Ophthalmic and Physiologic Optics. 2020; 41: 116-135. PubMed: https://pubmed.ncbi.nlm.nih.gov/33119189/
  13. Carnt N, Stapleton F. Strategies for the prevention of contact lens-related Acanthamoeba keratitis: a review. Ophtalmic and Physiol Optics. 2015; 36: 77-92. PubMed: https://pubmed.ncbi.nlm.nih.gov/26691018/
  14. Chkheidze R, Evers B, Cavuoti D, Merritt J, Hogan RN. Bilateral Acanthamoeba panophthalmitis: A rare and unique case. Amer J Ophthalmol Case Rep. 2020; 20: 100970. PubMed: https://pubmed.ncbi.nlm.nih.gov/33117918/
  15. Sen M, Honavar SG, Sharma N, Sachdev MS. COVID-19 eye: A review of ophthalmic manifestations of COVID-19. Ind J Ophtalmol. 2021; 69: 488-509. PubMed: https://pubmed.ncbi.nlm.nih.gov/33595463/
  16. Jones L, Walsh K, Willcox M, Morgan P, Nichols J. The COVID-19 pandemic: important considerations for contact lens practitioners. Cont Lens Anterior Eye. 2020; 43: 196-203. PubMed: https://pubmed.ncbi.nlm.nih.gov/32273245/
  17. Miller G. Researchers are tracking another pandemic, too - of coronavirus misinformation. Science. 2020.
  18. Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocul Immunol Inflamm 2020; 8: 391-395. PubMed: https://pubmed.ncbi.nlm.nih.gov/32175797/
  19. Kumar KK, Sampritha UC, Prakash AA, Adappa K, Chandraprabha S, et al. Ophthalmic manifestations in the COVID-19 clinical spectrum. Ind J Ophthalmol 2021; 69: 691-694. PubMed: https://pubmed.ncbi.nlm.nih.gov/33595502/
  20. Kinota S, Wong KW, Biswas J, Rao NA. Changing patterns of infectious keratitis: overview of clinical and histopathologic features of keratitis due to Acanthamoeba or atypical mycobacteria, and of infectious crystalline keratopathy. Indian J Ophthalmol. 1993; 41: 3-14. PubMed: https://pubmed.ncbi.nlm.nih.gov/8225521/
  21. Volkov VV, Zabaikina TP, Liu L, Astakhov ST, Gordeeva LM. Acanthamoeba keratitis (literature review and case report) (in Russian) Vestnik Oftalmologii. 1994; 110: 28-31.
  22. Dart Jk, Saw VP, Kilvington S. Acanthamoeba keratitis: diagnosis and treatment update 2009. Amer J Ophthalmol. 2009; 148: P487-499. E2. PubMed: https://pubmed.ncbi.nlm.nih.gov/19660733/
  23. Alkharashi M, Lindsley K, Law HA, Sikder S. Medical interventions for acanthamoeba keratitis. The Cochrane database of systematic reviews. 2015: CD010792. PubMed: https://pubmed.ncbi.nlm.nih.gov/25710134/
  24. Martinez AJ. Free-living amebas: infection of the central nervous system. Mount Sinai J Med. 1993; 60: 271-278. PubMed: https://pubmed.ncbi.nlm.nih.gov/8232369/
  25. Malet F, Hasle D, Flohic AM, Colin J. Superficial amebic keratitis (in French). J Francais d'Ophtalmol. 1993; 16: 165-169. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8496566
  26. Auran JD, Starr MB, Koester CJ, LaBombardi VJ. In vivo scanning slit confocal microscopy of Acanthamoeba keratitis. A case report. Cornea. 1994; 13: 183-185. PubMed: https://pubmed.ncbi.nlm.nih.gov/8156791/
  27. Nakagawa H, Kazami N, Izai K, Iwasaki M, Uchica Y, et al. Two cases of early Acanthamoeba keratitis (in Japanese). Nippon Ganka Gakkai Zasshi - Acta Societ Ophthalmol. Japon. 1993; 97; 544-50. PubMed: https://pubmed.ncbi.nlm.nih.gov/8317377/
  28. Bacon AS, Frazer DG, Dart JK, Matheson M, Ficker LA, et al. Acanthamoeba keratitis. The value of early diagnosis. Ophthalmology. 1993; 100: 1238-1243. PubMed: https://pubmed.ncbi.nlm.nih.gov/8341508/
  29. Wang L, Asem EK, McLaughlin GL. Calcium enhances Acanthamoeba polyphaga binding to extracellular matrix proteins. Invest Ophthalmol Visual Sci. 1994; 35: 2421-2426. PubMed: https://pubmed.ncbi.nlm.nih.gov/8163332/
  30. Gordon VR, Asem EK, Vodkin MH, McLaughlin GL. Acanthamoeba binds to extracellular matrix proteins in vitro. Ophthalmol Visual Sci. 1993; 34: 658-662. PubMed: https://pubmed.ncbi.nlm.nih.gov/8449684/
  31. Kilvington S. Acanthamoeba trophozoite and cyst adherence to four types of soft contact lens and removal by cleaning agents. Eye. 1993; 7: 535-538. PubMed: https://pubmed.ncbi.nlm.nih.gov/8253233/
  32. Van Klink F, Alizadeh H, He Y, Mellon JA, Silvany RF, et al. The role of contact lenses, trauma and Langerhans cells in a Chinese hamster model of Acanthamoeba keratitis. Invest Ophthalmol Visual Sci. 1993; 34: 1937-1944. PubMed: https://pubmed.ncbi.nlm.nih.gov/8491547/
  33. Volkov VV, Gordeva LM, Kaminskaia LIu, Zabaikina TP, Siu A. The diagnosis of Acanthamoeba keratitis. The identification of the first case in Russia (in Russian). Med Parazitol. Parazita. Bol. 1993; 5: 60-63. PubMed: https://pubmed.ncbi.nlm.nih.gov/8127276/
  34. Gautom RK, Lory S, Seyedirashthi S, Bergeron DL, Fritsche TR. Mitochondrial DNA fingerprinting of Acanthamoeba spp. isolated from clinical and environmental sources. J Clin Microbiol. 1994; 32: 1070-1073. PubMed: https://pubmed.ncbi.nlm.nih.gov/7913095/
  35. Karsenti N, Lau R, Purssell A, Chong-Kit, Cunanam M, et al. Development and validation of a real-time PCR assay for the detection of clinical amoebae. BMC Res Notes. 2017; 10: 355. PubMed: https://pubmed.ncbi.nlm.nih.gov/28754142/
  36. Gardner A. Pathogenesis of Acanthamoebic keratitis: hypothesis based on a histological analysis of 30 cases. Br J Ophtalmol. 1993; 77: 366-370. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC504533/
  37. Kremer J, Cohen EJ, Eagle RC Jr, Udell I, Laibson PR. Histopathologic evaluation of stromal inflammation in Acanthamoeba keratitis. CLAO J. 1994; 20: 45-48. PubMed: https://pubmed.ncbi.nlm.nih.gov/8149574/
  38. Gieryng R, Prost M, Gieryng H, Mazur T, Kasprzak W. Amebic keratitis-keratitis Acanthamoeba (in Polish) Klinika Oczna. 1994; 96: 163-167. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/7990337
  39. Pogson C. Acanthamoeba keratitis. J Opthalmol Nurs Tech. 1993; 12: 114-116. PubMed: https://pubmed.ncbi.nlm.nih.gov/8158668/
  40. Varga JH, Wolf TC, Jensen HG, Parmley VC, Rowsey JJ. Combined treatment of Acanthamoeba keratitis with propamidine, neomycin, and polyhexamethylene biguanide. Am J Ophthalmol. 1993; 115: 466-470. PubMed: https://pubmed.ncbi.nlm.nih.gov/8470718/
  41. Tay-Kearney ML, McGhee CM, Crawford GJ, Trown K. Acanthamoeba keratitis. A masquerade of presentation in six cases. Aust NZJ Ophthalmol. 1993; 21: 237-245. PubMed: https://pubmed.ncbi.nlm.nih.gov/8148140/
  42. Brasseur G, Favennec L, Perrine D, Chenu JP, Brasseur P. Successful treatment of Acanthamoeba keratitis by hexamidine. Cornea. 1993; 13: 459-462. PubMed: https://pubmed.ncbi.nlm.nih.gov/7995072/
  43. Seal DV, Hay J, Kirkness CM. Chlorhexidine or polyhexamethylene biguanide for Acanthamoeba keratitis. Lancet. 1995; 345: 136. PubMed: https://pubmed.ncbi.nlm.nih.gov/7815880/
  44. Dougherty PJ, Binder PS, Mondino BJ, Glasgow BJ. Acanthamoeba sclerokeratitis. Am J Ophthalmol. 1994; 117: 475-479. PubMed: https://pubmed.ncbi.nlm.nih.gov/8154529/
  45. Nilsson SEM, Montan PG. The hospitalized cases of contact lens induced keratitis in Sweden and their relation to lens type and wear schedule: results of a three-year retrospective study. CLAO J. 1994; 20: 97-101. PubMed: https://pubmed.ncbi.nlm.nih.gov/8044983/
  46. Panjwani N. Pathogenesis of acanthamoeba keratitis. Ocul Surf. 2010; 8: 70-79. PubMed: https://pubmed.ncbi.nlm.nih.gov/20427010/
  47. Carnt N, Hoffman JJ, Verma S, Hau S, Radford CF, et al. Acanthamoeba keratitis: confirmation of the UK outbreak and a prospective case-control study identifying contributing risk factors. Brit J Ophthalmol. 2018; 102: 1621-1628. PubMed: https://pubmed.ncbi.nlm.nih.gov/30232172/
  48. Tananuvat N, Techajongjintana N, Somboon P, Wannasan A. The First Acanthamoeba Keratitis case of non-contact lens wearer with HIV infection in Thailand. Case Report. The Korean J Parasitol. 2019; 57: 505-511. PubMed: https://pubmed.ncbi.nlm.nih.gov/31715691/
  49. Chukwuma Sr C. The clinicopathological correlates of cystoisosporiasis in immunocompetent, immunocompromised and HIV-infected/AIDS patients, but neglected in SARS-COV-2/COVID-19 patients? Int J Clin Microbiol Biochem Technol. 2021; 4: 001-004.https://www.heighpubs.org/hcmbt/pdf/ijcmbt-aid1018.pdf

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More